Stockwinners Market Radar for February 08, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EST Cathie Wood's ARK Investment bought 140.7K shares of CareDx today

18:56 EST Nestle Purina recalls select lots of dry dog food over vitamin D concerns - Nestle Purina PetCare Company is voluntarily recalling select lots of Purina Pro Plan Veterinary Diets EL Elemental prescription dry dog food due to potentially elevated levels of vitamin D. Vitamin D is an essential nutrient for dogs; however, ingestion of elevated levels can lead to health issues depending on the level of vitamin D and the length of exposure. Vitamin D toxicity may include vomiting, loss of appetite, increased thirst, increased urination, and excessive drooling to renal dysfunction. Purina is taking this action after receiving two contacts about two separate confirmed cases of a dog exhibiting signs of vitamin D toxicity after consuming the diet, to date. Once taken off the diet, each of these dogs recovered. The affected dry dog food was distributed throughout the United States by prescription only through veterinary clinics, Purina Vet Direct, Purina for Professionals, and other select retailers with the ability to validate a prescription.

18:49 EST Regeneron's Eylea injection approved by FDA for treatment of preterm infants - Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration has approved EYLEA Injection to treat preterm infants with retinopathy of prematurity. Following this first pediatric approval, EYLEA is now indicated to treat five retinal conditions caused by ocular angiogenesis. "Retinopathy of prematurity is a leading cause of childhood blindness worldwide. Until now, the only FDA-approved treatment in common use was laser photocoagulation, a complex and lengthy procedure that permanently ablates retina tissue and is stressful not only for infant patients but also the family navigating a delicate time after a preterm birth," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, and a principal inventor of EYLEA. "For the first time, physicians will now have an FDA approved medication in EYLEA to treat this heartbreaking disease in these smallest of patients. We thank the investigators and the many families who participated in the clinical trials."

18:35 EST Cardiovascular Systems trading resumes

18:24 EST Agco CEO: The market for our products is extremely strong - In an interview on CNBC's Mad Money, Eric Hansotia said the company's order books are very extended. He's seeing strong demand in North America and Europe and expects strong farmer profitability into 2024. Fertilizer and diesel prices are coming down from inflationary levels, he added. "We aim to make the machines more productive and the farmers more profitable," he noted.

18:10 EST Mesoblast says FDA grants RMAT designation for rexlemestrocel-L - Mesoblast Limited announced that the United States Food and Drug Administration's Office of Tissues and Advanced Therapies has granted Regenerative Medicine Advanced Therapy designation for rexlemestrocel-L in the treatment of chronic low back pain associated with disc degeneration, in combination with hyaluronic acid as delivery agent for injection into the lumbar disc. RMAT designations aim to expedite the development of regenerative medicine therapies intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for the disease or condition. An RMAT designation for rexlemestrocel-L provides all the benefits of Breakthrough and Fast Track designations, including rolling review and eligibility for priority review on filing of a Biologics License Application.

18:02 EST Cardiovascular Systems trading halted, news pending

17:55 EST BOK Financial director Bangert sells $771K in company shares - Director of BOK Financial Steven Bangert disclosed in a regulatory filing that he had sold 7,500 shares of company stock at $102.80 per share on February 7, for a total transaction amount of $771,000.

17:19 EST Twitter Blue debuts longer Tweets with up to 4,000 characters - Twitter Blue said, in part in a tweet: "Need more than 280 characters to express yourself? we know that lots of you do... and while we love a good thread, sometimes you just want to Tweet everything all at once. we get that. so we're introducing longer Tweets! you're gonna want to check this out. tap this starting today, if you're subscribed to Twitter Blue in the US you can create longer Tweets. most standard functions of Tweeting still apply, whether you want to post a picture, use a hashtag, or create a poll. but now you can type all the way up to 4,000 characters. for now, longer Tweets on web can't be saved as drafts or scheduled to send later." Reference Link

17:09 EST Eiger BioPharmaceuticals announces publication of TOGETHER study data in NEJM - Eiger BioPharmaceuticals announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine, or NEJM. The study, which evaluated newly diagnosed outpatients with mild-to-moderate COVID-19, found that among predominantly vaccinated participants with COVID-19, a single-dose treatment with Eiger's investigational agent, peginterferon lambda, resulted in significantly decreased clinical events. The manuscript titled "Effect of Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients" will be published in the February 9, 2023 issue of NEJM and follows the topline safety and efficacy data announced. The company said, "The primary endpoint was a composite endpoint of COVID-19-related hospitalization or emergency room visits greater than six hours. Secondary endpoints included SARS-CoV-2 viral clearance, all-cause hospitalization, mortality due to COVID-19, days in hospital and on ventilator, and adverse events. In the study, 931 patients received peginterferon lambda and 1018 received placebo. This was among the first trials to include a predominantly vaccinated population with 84% of the population having received vaccination prior to study entry. The study period included emergence of multiple COVID-19 variants of concern. The publication detailed results, highlighting a 51% reduction in COVID-19-related hospitalizations or emergency room visits greater than six hours (the primary outcome) for participants receiving peginterferon lambda vs. placebo, with 2.7% (25 of 931) of participants randomized to peginterferon lambda experiencing a primary outcome event, compared with 5.6% (57 of 1018) (relative risk 0.49, 95% Bayesian credible interval 0.30-0.76, posterior probability greater than99.9%) among patients randomized to placebo. This effect was maintained in subgroup analyses including COVID-19-related hospitalization alone (relative risk 0.57, 95% Bayesian credible intervals 0.33-0.95) and COVID-19-related hospitalization or death (hazard ratio 0.59, 95% Bayesian credible interval 0.35-0.97). The effects were consistent across dominant variants and vaccination status. Among individuals with a high viral level at baseline, peginterferon lambda resulted in lower viral loads and a higher percentage of patients clearing SARS-COV-2 RNA by Day 7, compared to placebo. The incidence of adverse events was similar in the two groups. Primary events in the study happened a median of 5 days (interquartile range 3 to 7 days) after randomization. The treatment effect for peginterferon lambda was more pronounced in patients who were treated within 3 days of symptom onset. Peginterferon lambda was consistent in the direction of effect on all secondary outcomes. Risk of COVID-19 hospitalization or all-cause death was reduced by 47% (hazard ratio, 0.53, 95% Bayesian credible interval 0.31 to 0.91) in participants receiving peginterferon lambda. In patients receiving treatment within 3 days of symptom onset, greater treatment effects were observed in the peginterferon lambda group, including 65% reduction of COVID-19 related hospitalization (hazard ratio 0.35, 95% Bayesian credible interval 0.15 -0.75), 81% risk reduction in all-cause death (relative risk 0.19 [0/567 vs 3/590], 95% Bayesian credible interval 0.01-1.57) and 89% risk reduction among unvaccinated patients (hazard ratio, 0.11; 95% Bayesian credible interval, 0.01 to 0.83). There was one COVID-19-related death in the peginterferon lambda group and four in the placebo group. Incidence of any treatment emergent adverse events was similar between peginterferon lambda and placebo groups, which were primarily injection site reactions."

17:05 EST Disney says expects restructuring to achieve $5.5B in cost savings - Sees FY23 capital expenditures $6B. Says sequel in the works for "Toy Story," "Frozen" and "Zootopia." Says ESPN linear ratings were up 8% overall. Says expects pressure to continue into Q2. Says ARPU fell xxx%. Says Disney+ domestic price increase has gone as expected. Says core Dis + subs may only grow modestly in Q2. Says higher core sub growth toward end of fiscal year. ays pleased with initail response to Dis+ ad tier. Says Q1 ESPN ad revenue was down 4%. Says anticipated Q2 will have most challenging comparison for linear networks. Says will likely to be able to declare a small dividend before the end of the year.

17:04 EST Bright Minds Biosciences receives noncompliance letter from Nasdaq - Bright Minds Biosciences announced that it has received a letter from the Nasdaq, stating that following the resignation of Dr. Williamson from the company's board of directors and audit committee, the Company no longer complies with Nasdaq's independent director and audit committee requirements as set forth in Listing Rule 5605.

17:03 EST Hyperfine names Brett Hale chief administrative office, CFO - Hyperfine announced that Brett Hale will join Hyperfine on February 13 and will serve as chief administrative officer and chief financial officer, or CFO. Alok Gupta, who currently serves as CFO, will step down on or about March 31 after a transition period. Prior to Hyperfine, Hale served as CFO of Bigfoot Biomedical.

16:58 EST TTM Technologies plans to close three manufacturing facilities, cut 750 jobs - TTM Technologies announced that it plans to close three manufacturing facilities in order to improve total plant utilization, operational performance, customer focus and profitability. TTM intends to close PCB manufacturing operations in Anaheim and Santa Clara, California, and Hong Kong and to consolidate the business from these impacted sites into TTM's remaining facilities. The plant closures are expected to improve both facility and talent utilization across our footprint resulting in improved profitability. TTM expects to continue to support impacted customers at its remaining manufacturing sites. TTM expects to close these three sites over the course of this year and, where appropriate, transfer employees to other facilities nearby. For those employees who do not transfer, TTM plans to offer long notice periods, severance compensation, and extended medical coverage. The company expects a total reduction of approximately 750 employees, which is approximately 5% of the global workforce in conjunction with the consolidation and resulting plant closures. The company expects to record between $22M and $28M in separation, asset impairment and disposal costs related to this restructuring, primarily between now and the end of 2023. Approximately 80% of these costs are expected to be in the form of cash expenditures and the rest in the form of non-cash charges. These actions are expected to yield an annual operating profit increase of approximately $22 to $27 million after the facilities are closed and the transferred business is fully assimilated within our remaining footprint.

16:56 EST Galapagos says two induction cohorts in trial of filgotinib missed endpoints - The company states: "Galapagos NV announced the topline results from DIVERSITY, a global Phase 3 trial to evaluate the safety and efficacy of filgotinib, 100mg or 200mg once daily, during induction and maintenance treatment of biologic-naive and biologic-experienced patients with moderate to severe Crohn's disease. The co-primary endpoints at Week 10 and Week 58 were clinical remission per Patient Reported Outcome (PRO-2) and endoscopic response per Simple Endoscopic Score for Crohn's Disease (SES-CD). Induction Cohort A included biologic-naive (54%) and biologic-experienced (46%) patients; induction Cohort B included biologic-experienced patients. In total, 33% of patients in Cohort A and 52% of patients in Cohort B had failed treatment with 3 or more biologic drugs. Both induction cohorts of the study failed to meet the co-primary endpoints of clinical remission and endoscopic response for filgotinib, 100mg and 200mg once daily. In the maintenance phase of the study, a statistically significant higher proportion of patients receiving filgotinib 200mg once daily achieved the co-primary endpoints of clinical remission and endoscopic response compared to placebo at Week 58. The safety observations of the study were in line with the underlying disease and were consistent with the safety profile of filgotinib in previous studies across indications."

16:54 EST Galapagos down 5% at $41.49 per share after resumption of trade

16:52 EST Dropbox Chairman Houston sells over $3.8M in company shares - Chairman of Dropbox Andrew Houston disclosed in a regulatory filing that he had sold162,500 shares of company stock at $23.56 per share on February 6, for a total transaction amount of $3,828,695. I

16:49 EST Post Holdings to acquire select pet food brands from J.M. Smucker for $1.2B - Post Holdings announced it has signed a definitive agreement in which Post will acquire select pet food brands from The J.M. Smucker Co. for $1.2B. The transaction includes leading dog and cat food brands such as Rachael Ray Nutrish, Nature's Recipe, 9Lives, Kibbles 'n Bits and Gravy Train, which together generated net sales of $1.4B in the year ended April 30. Post also is acquiring manufacturing and distribution facilities in Bloomsburg, Pennsylvania and manufacturing facilities in Meadville, Pennsylvania and Lawrence, Kansas. The acquisition will provide Post with a compelling entry point into the attractive and growing pet food category. Post is acquiring an established, scaled position in the mainstream and entry premium sub-categories. Post management expects there to be additional opportunities for future investments in the pet food category.

16:45 EST TFF Pharmaceuticals appoints Harlan Weisman, M.D as CEO - TFF Pharmaceuticals announced the appointment of Harlan Weisman, M.D. as permanent Chief Executive Officer. TFF Pharmaceuticals will hold a conference call and webcast on February 16 to provide an overview of the Company's corporate strategy and objectives for 2023, which will include formal remarks from Dr. Weisman and the Company's recently appointed Chief Medical Officer, Zamaneh Mikhak, M.D.

16:44 EST Aligos announces portfolio reprioritization of NASH, extends cash runway - Aligos Therapeutics (ALGS) announced a portfolio reprioritization. Aligos' highest priorities will be focused on rapid advancement of its clinical NASH and COVID-19 programs as well as maintaining its ongoing NASH oligonucleotide research collaborations with Merck & Co(MRK) . Additionally, the Company plans to complete the =48-week and single ascending dose cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations. This portfolio reprioritization is being accompanied by a reduction of the Company's current workforce of approximately 10% and, combined with careful workforce management, including employee attrition and targeted hiring, has resulted in an overall workforce reduction of approximately 25% since the beginning of January 2022.As a result of the portfolio reprioritization, realignment of its workforce, and other cost-saving measures, the Company expects to maintain a strong balance sheet and extend its projected cash runway to the end of 2024. The Company expects to report Q4 and 2022 year-end financial results as well as provide guidance regarding the amount of anticipated one-time charges related to the reprioritization, which we expect to record in Q1 2023, in mid-March 2023. "With such a diverse clinical portfolio, including four drug candidates in or near the clinic, as well as maintaining a strong discovery engine, where we continue to support multiple research collaborations, we determined that Aligos would be best positioned to achieve its business objectives by taking action now to streamline operations, reprioritize its portfolio, and implement certain cost-saving measures, including a reduction in force," said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. "I would like to express my sincere gratitude to the employees who are being affected by this reprioritization. We are grateful for their dedicated service and contributions to Aligos' mission."

16:38 EST J.M. Smucker to divest sell several pet food brands to Post Holdings for $1.2B - The J.M. Smucker Co. (SJM) announced it has entered into a definitive agreement to sell several pet food brands to Post Holdings (POST) headquartered in St. Louis, Missouri. The transaction is valued at approximately $1.2B, consisting of $700M in cash and approximately 5.39M shares of common stock of Post Holdings. The transaction includes the Rachael Ray Nutrish, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Gravy Train brands as well as the company's private label pet food business. The transaction includes relevant trademarks and licenses, and the company's manufacturing and distribution facilities in Bloomsburg, Pennsylvania, as well as its manufacturing facilities in Meadville, Pennsylvania and Lawrence, Kansas. In addition, a group of employees will transition to Post Holdings, Inc. to support the business. The company expects these brands to generate net sales of approximately $1.5B for the fiscal year ended April 30, which are primarily reported in the U.S. Retail Pet Foods segment. The Company expects the divestiture to be dilutive to its adjusted earnings per share by approximately 45c on a full-year basis, reflecting the foregone profit related to the divested brands and before factoring in any benefits from the use of transaction proceeds and the impact of stranded overhead costs. The company anticipates replacing the divested earnings through the deployment of transaction proceeds and mitigating the impact of stranded overhead costs through initiatives within its Transformation Office over time. The transaction is anticipated to close in the fourth quarter of the company's current fiscal year ending April 30, subject to closing conditions including the receipt of required regulatory approvals.

16:35 EST O'Reilly Automotive reports Q4 SSS up 9.0%

16:33 EST Cohen & Steers reports preliminary AUM $87.3B as of January 31 - An increase of $6.9B from assets under management at December 31, 2022. The increase was due to net inflows of $322M and market appreciation of $6.7B, partially offset by distributions of $190M.

16:31 EST AppLovin jumps 28% to $16.18 after Q4 results and guidance

16:30 EST Galapagos NV trading resumes

16:25 EST Lincoln National reports Q4 book value per share at $18.41 - The company states: "As of December 31, 2022, book value per share, including AOCI, decreased 84% from the prior-year period to $18.41. Book value per share, excluding AOCI, decreased 18% from the prior-year period to $63.73."

16:21 EST PHX Minerals sees 2023 total production 8,600-10,000 Mmcfe - From total 2022 production of 9,697 Mmcfe.

16:18 EST MGM Resorts CEO says 'strong momentum in our business' - "We achieved our fifth consecutive quarter of record-breaking Las Vegas Strip Resorts Adjusted Property EBITDAR in the fourth quarter," said Bill Hornbuckle, CEO and President of MGM Resorts. "What we accomplished in 2022 is nothing short of remarkable, and is a testament to our strategic plan, scale, brand strength, talented team, loyalty program, and the diverse geographies and channels in which we operate. We believe that there is strong momentum in our business and our 2023 outlook remains bright, driven by a robust events calendar domestically, MGM China's rapid year-to-date return to profitability and BetMGM's ongoing improvement in 2023." "We achieved exceptional results in the fourth quarter and remain optimistic in our outlook for this year. We are also focused on free cash flow and believe our company presents a compelling yield, especially when taking into account the value in our share price for excess cash, our ownership value of MGM China and BetMGM," said Jonathan Halkyard, CFO and Treasurer of MGM Resorts. "Our share buyback program continues to return capital to shareholders as we have already repurchased 4 million shares for $164 million year-to-date, adding to the 76 million shares we repurchased in 2022 and totaling approximately $4.7 billion since 2021. Beyond this, our Board of Directors authorized an additional $2 billion for share buybacks."

16:17 EST MGM Resorts announces new $2B share repurchase program

16:16 EST Affirm cuts 2023 outlook amid macroeconomic headwinds - The company said, "We continue to expect to achieve a sustained profitability run rate, on an Adjusted Operating Income basis, as we exit fiscal year 2023. However, we are reducing our outlook for FY'23. We are confident that our teams are prioritizing the right initiatives as we work to offset the macroeconomic headwinds we have faced during the last several quarters, and we expect to continue to operate the business with a conservative credit posture while navigating extremely volatile capital markets."

16:16 EST Robinhood cancels almost $500M of share-based compensation awards - CEO Vlad Tenev and Baiju Bhatt announced that they cancelled their 2021 pre-IPO market-based restricted stock unit awards which total 35.5M of currently unvested shares. This lowers our GAAP operating costs by up to $50M per quarter starting in Q2, and it has already reduced our fully diluted share count by 3.5 percent. The company said, "We will also record a one-time accounting charge related to the cancellation of founder share based compensation in Q1 2023, which is expected to be roughly $485 million."

16:13 EST Affirm to reduce workforce by 19%, effective today - Affirm CEO Max Levchin said, "Today, we are reducing the size of our team by 19%. This was the single most difficult decision I have had to make since Affirm's founding, but I believe it is the right one. I take full responsibility for it and the actions that led us to this point. Growing rapidly over the last few years, and especially through the pandemic, we hired ahead of the revenue required to support the size of the team. This was a deliberate decision, as Affirm's opportunities are compelling and plentiful. The volume growth and strong unit economics we posted gave us confidence in this approach and a clear path to our profitability objectives. In a period of increased economic uncertainty, we are doubling down on our core businesses, delaying projects with less certain revenue timelines, and aligning our operating expenses with revenue. Concurrent with reducing our workforce, we are sunsetting several initiatives, such as Affirm Crypto."

16:11 EST Amtech Systems books over $8M in thermal systems for EV supply chain - Amtech Systems announced the receipt of multiple follow-on orders for controlled atmosphere belt furnaces for thermal processing of assemblies and substrates used in electric vehicle production. These repeat orders were received by Amtech division, BTU International, for multiple controlled atmosphere furnaces with delivery starting in the second half of calendar 2023 and into calendar 2024. These continuous furnaces will be used in applications including brazing and sintering for assemblies and substrates that are used in EV battery cooling and electronic controls. The furnaces will be produced at BTU's factory in the USA and shipped to customer locations in Asia, Europe and North America. "Controlled atmosphere belt furnaces possess the unique ability to both keep thermal process conditions tightly controlled and consistent while producing extremely high volumes of product," said Michael Whang, CEO of Amtech Systems. "The fact that we are seeing these systems being used in so many critical applications for the EV supply chain is an indicator of the transition to volume production and scale for the industry. BTU is uniquely suited for this opportunity with the existing customer base concentrated in the automotive supply chain," added Whang.

16:10 EST Lincoln National names Christopher Neczypor CFO - Lincoln Financial announced that Christopher Neczypor will be appointed Executive Vice President, Chief Financial Officer, effective February 17, 2023. Neczypor, who currently serves as Executive Vice President, Chief Strategy Officer, will succeed Randal Freitag, who is leaving the company. Freitag will remain with Lincoln Financial through the end of the first quarter of 2023 and will work closely with Neczypor to ensure a smooth transition. Neczypor will continue to report to President and CEO Ellen Cooper and will continue to be a member of the company's Senior Management Committee. He will be responsible for corporate finance, corporate tax, corporate actuarial, accounting, treasury, investor relations, mergers and acquisitions and corporate development. "Chris has extensive life insurance and financial industry experience - he brings background as a strategic leader inside insurance organizations as well as an external perspective from his time working in the life insurance sector as an analyst and investor. Throughout his career, he has cultivated an incredibly deep knowledge of the complexities of insurance financials," said Cooper. "Since joining Lincoln in 2018, he has made many significant and valuable contributions to the organization including quarterbacking the shift to our enterprise strategic objectives, and with his eye for outstanding talent, building and developing several strong and experienced teams. Chris and I have worked alongside each other for five years, and I know that with his deep financial acumen, analytical expertise, and knowledge of our business he will be an excellent financial steward as we further strengthen our capital position and build for the future of Lincoln."

16:09 EST Disney reports Q1 Media and Entertainment Distribution revenue $14.7B, up 1% y/y - Reports Q4 Disney Parks, Experiences and Products revenue $8.74B, up 21% from the prior year.

16:08 EST Disney reports 161.8M Disney+ paid subscribers as of Dec. 31 - Reports Disney+ paid subscribers of 161.8M as of December 31, 2022, down from 164.2M as of October 1, 2022. Reports ESPN+ paid subscribers of 24.9MM, up from 24.3M as of October 1. Reports total Hulu paid subscribers of 48.0M, up from 47.2M three months prior.

16:08 EST Mattel expects to resume share repurchases in 2023

16:00 EST Galapagos NV trading halted, news pending

14:48 EST B. Riley Financial exec Moore acquires 20,000 common shares - In a regulatory filing, B. Riley Securities CEO Andrew Moore disclosed the purchase of 20,000 common shares of B. Riley Financial on February 8 at a price of $38.7464 per share.

14:32 EST Google announces AI-powered Immersive View for Maps - Google announces Immersive View for Google Maps, an "an immersive, intuitive map that reimagines how you explore and navigate, while helping you make more sustainable choices." The company said the new feature demonstrates how artificial intelligence brings the vision to life. "Immersive view is an entirely new way to explore a place - letting you feel like you're right there, even before you visit," the company said in a blog post. "Using advances in AI and computer vision, immersive view fuses billions of Street View and aerial images to create a rich, digital model of the world. And it layers helpful information on top like the weather, traffic, and how busy a place is. Say you're planning a visit to the Rijksmuseum in Amsterdam. You can virtually soar over the building and see where things like the entrances are. With the time slider, you can see what the area looks like at different times of day and what the weather will be like. You can also spot where it tends to be most crowded so you can have all the information you need to decide where and when to go. If you're hungry, glide down to the street level to explore nearby restaurants - and even take a look inside to quickly understand the vibe of a spot before you book your reservation. To create these true-to-life scenes, we use neural radiance fields (NeRF), an advanced AI technique, transforms ordinary pictures into 3D representations. With NeRF, we can accurately recreate the full context of a place including its lighting, the texture of materials and what's in the background. All of this allows you to see if a bar's moody lighting is the right vibe for a date night or if the views at a cafe make it the ideal spot for lunch with friends." Immersive view starts rolling out today in London, Los Angeles, New York, San Francisco and Tokyo. And in the coming months, it'll launch in even more cities, including in Amsterdam, Dublin, Florence and Venice. Reference Link

14:12 EST Netflix provides update on sharing guidelines as 100M households share accounts - In an "update on sharing," Netflix said that, "Today, over 100 million households are sharing accounts - impacting our ability to invest in great new TV and films. So over the last year, we've been exploring different approaches to address this issue in Latin America, and we're now ready to roll them out more broadly in the coming months, starting today in Canada, New Zealand, Portugal and Spain. Our focus has been on giving members greater control over who can access their account. Set primary location: We'll help members set this up, ensuring that anyone who lives in their household can use their Netflix account. Manage account access and devices: Members can now easily manage who has access to their account from our new Manage Access and Devices page. Transfer profile: People using an account can now easily transfer a profile to a new account, which they pay for - keeping their personalized recommendations, viewing history, My List, saved games and more. Watch while you travel: Members can still easily watch Netflix on their personal devices or log into a new TV, like at a hotel or holiday rental. Buy an extra member: Members on our Standard or Premium plan in many countries (including Canada, New Zealand, Portugal and Spain) can add an extra member sub account for up to two people they don't live with - each with a profile, personalized recommendations, login and password - for an extra CAD$7.99 a month per person in Canada, NZD$7.99 in New Zealand, Euro 3.99 in Portugal, and Euro 5.99 in Spain."

14:04 EST Tesla CEO says 'Master Plan 3' to be presented on March 1 - Tesla CEO Elon Musk said last night that his so-called "Master Plan 3," which he describes as the "path to a fully sustainable energy future for Earth," will be presented at the comapny's March 1 Investor Day. Reference Link

13:56 EST Third Point updates on Colgate-Palmolive, DuPont, PG&E positions - In its quarterly letter to investors, Third Point stated: "Colgate (CL) remains one of the firm's largest equity positions. The company offers defensive growth at a reasonable valuation, and we continue to see the potential for shares to deliver attractive risk adjusted returns over the next several years. Fourth Quarter results were disappointing... We believe some of this "miss" was beyond the company's control and that Colgate is on the road to delivering more predictable results... There are many appealing paths to additional value creation at Colgate and we hope the Board and management team will now devote more attention to portfolio management... We recently increased our investment in DuPont (DD), a specialty chemical company run by legendary value creator Ed Breen, who is leading a corporate transformation... We expect the combined catalysts of increased share repurchases, the pending resolution of legal claims, and the new business structure to drive meaningful value for shareholders... As we enter our fifth year as investors in PCG, first as bondholders and then as shareholders, we remain as enthusiastic as ever about the company's potential. Even with a 63% increase in the share price over the past six months, we believe the Company remains significantly undervalued with a risk-reward skewed almost entirely to the upside."

13:50 EST Third Point initiated position in AIG during Q4 - Third Point revealed in its quarterly letter to investors that the firm had initiated a position in AIG during Q4. "Third Point initiated a position in AIG during the Fourth Quarter. AIG is a global P&C insurer that, until recently, held a life insurance subsidiary, Corebridge. AIG has undergone a massive overhaul since the global financial crisis. The current executive team, who started in 2017, has made significant progress turning around the P&C insurance operations that previously suffered from unprofitable underwriting, significant loss volatility, and inadequate reserving," the firm stated.

13:07 EST Medtronic announces late-breaking clinical data from STROKE AF trial - Medtronic announced late-breaking clinical data from the STROKE AF clinical study, which the company said "showed large and small vessel disease stroke patients had a 10-fold increase in AF detection with the Reveal LINQ insertable cardiac monitor, ICM, at three years compared to patients randomized to standard of care who did not receive continuous, long-term monitoring." The latest results, presented today as a late-breaking clinical trial at the American Stroke Association's International Stroke Conference 2023, "build on the STROKE AF study 12-month primary endpoint results published in JAMA in June 2021," the company stated.

12:39 EST Bill Anderson to become CEO of Bayer AG - The Supervisory Board of Bayer AG (BAYRY) has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board of Management on April 1, 2023. Bill Anderson was elected unanimously after a thorough selection process which began mid last year. Werner Baumann, current CEO of Bayer, will work closely with him on a smooth transition before retiring from Bayer after 35 years of service at the end of May 2023. Bill Anderson, a chemical engineer by education, has served in various leadership positions in the life science industry over the past 25 years. Most recently, he served as CEO of Roche's (RHHBY) Pharmaceuticals Division, where he led a comprehensive transformation program which resulted in many new product launches, revenue growth, and greater productivity across the organization. Reference Link

12:29 EST ReShape Lifesciences Inc trading resumes

12:24 EST ReShape Lifesciences Inc trading halted, volatility trading pause

12:01 EST DHI Group falls -21.7% - DHI Group is down -21.7%, or -$1.32 to $4.75.

12:00 EST Capri Holdings falls -27.0% - Capri Holdings is down -27.0%, or -$17.90 to $48.46.

12:00 EST Kyndryl Holdings rises 16.5% - Kyndryl Holdings is up 16.5%, or $2.24 to $15.81.

11:24 EST Corning raises quarterly dividend 3.7% to 28c per share - Corning's Board of Directors declared a quarterly dividend of 28c per share, a 3.7% increase versus the company's previous quarterly common stock dividend of 27c. The dividend will be payable on March 30, 2023, to shareholders of record on Feb. 28, 2023.

10:35 EST Riskified establishes entity in Tokyo, Japan - Riskified has established an entity in Tokyo naming Anthony Guercio as Country Manager. Guercio is leading Riskified's efforts to help Japanese merchants automate fraud management and safely and profitably grow their online business. The company said, "As an example of Riskified's success in Japan, DMM.com recently chose Riskified's fraud prevention solution, Chargeback Guarantee, for complete protection against fraud and chargeback costs. DMM.com joins giftee Inc. and other prominent Japanese companies in relying on Riskified's risk intelligence platform, giving them access to fraud prevention analytics and insights through a fully localized dashboard."

10:14 EST Meten introducing ChatGPT to under-construction Web3 education platform - Meten Holding announced that the company intends to introduce ChatGPT to its under-construction Web 3 education platform. The company said in a statement: "We believe that ChatGPT has the potential to become a new engine for innovation and development in the education industry. 1) ChatGPT can take on information mining, material invocation, replication editing, and teaching evaluations at a high level, technically fulfilling personalized education needs with low marginal costs and high efficiency. 2) ChatGPT can nurture new forms and modes of education through supporting the multidimensional interaction and integration of digital content with the traditional education industry. 3) It will help the development of the education industry, provide quality content creation, integrate data services and application scenarios, and build a perfect closed loop for a new education ecology."

10:08 EST Wolfpack Research short B. Riley Financial, says 'crumbling before our eyes' - Wolfpack Research is short B. Riley Financial, calling it "a bottom-feeder investment bank that is crumbling before our eyes" in a recently published report. "As financial conditions have contracted, RILY has not sobered up and cut its losses on failing investments, instead it has extended its distressed clients more capital so that it can pretend that better times are just around the corner," the report reads. "Our research shows it 1) overleveraged to buy speculative assets during the financial mania of 2020-2021 and 2) lent money to companies that have degenerated into zombies. RILY's total cash and investments, net of debt, fell by $950 million to -$350 million during 2022. Further, we believe RILY will record investment losses of up to ~$700 million in 2023, putting its dividend at risk, and potentially triggering a collapse of the firm." Shares of B. Riley Financial have dropped about 4% to $42.45 in Wednesday morning trading. Reference Link

10:07 EST Carvana trading halted, volatility trading pause

10:00 EST DHI Group falls -14.7% - DHI Group is down -14.7%, or -89c to $5.18.

10:00 EST Capri Holdings falls -23.4% - Capri Holdings is down -23.4%, or -$15.56 to $50.80.

10:00 EST BigBear.ai rises 15.3% - BigBear.ai is up 15.3%, or 75c to $5.67.

09:52 EST Titan Medical trading resumes

09:47 EST Xponential Fitness falls -12.4% - Xponential Fitness is down -12.4%, or -$3.44 to $24.40.

09:47 EST Capri Holdings falls -21.0% - Capri Holdings is down -21.0%, or -$13.94 to $52.42.

09:47 EST New Relic rises 20.4% - New Relic is up 20.4%, or $13.19 to $77.77.

09:34 EST Titan Medical to resume trading at 9:50 am ET - Shares of Titan Medical are set to resume quotation at 9:45 am ET and resume trading at 9:50 am ET, according to Nasdaq. The stock was halted, news pending, before the company provided an update to the market on its previously announced review and evaluation of strategic alternatives and disclosed that none of "over 40 potential counterparties" expressed an interest in acquiring the company's business.

09:26 EST 374Water, Inc. to conduct field demonstration of AirSCWO system - 374Water has partnered with WSP to demonstrate the efficacy of the AirSCWOTM 6 as a scalable, mobile and field-ready solution for destruction of per-and polyfluoroalkyl substances at U.S. Air Force bases. This work will be performed under an AFCEC Broad Agency Announcement contract awarded to WSP by the Air Force Civil Engineer Center's Environmental Directorate. The AFCEC BAA contract comes at a time when the Department of Defense is actively seeking solutions for PFAS remediation, and the awarded project will be the first field-scale case study to use SCWO technology to destroy the PFAS-laden spent media generated from the groundwater pump and treat remediation systems.

09:21 EST Cassava Sciences provides enrollment update for Phase 3 studies of simufilam - Cassava Sciences announced an update on patient enrollment for its on-going Phase 3 clinical studies of simufilam for the treatment of Alzheimer's disease dementia. Simufilam, an oral drug, is Cassava Sciences' proprietary lead drug candidate. A total of 953 Alzheimer's patients are now enrolled across Cassava Sciences' Phase 3 studies. For each Phase 3 study, patient enrollment has passed the halfway mark of the target patient enrollment. The enrollment target for both Phase 3 clinical studies is approximately 1,750 patients with mild-to-moderate Alzheimer's disease who also meet other study eligibility criteria. There are no interim analyses in Cassava Sciences' Phase 3 studies.

09:20 EST Humana and ChenMed announce five-year network agreement - ChenMed, a senior-focused primary care providers in the United States, and leading health and well-being company Humana have signed a new five-year agreement providing in-network care for Humana's Medicare Advantage members at all ChenMed locations, including Chen Senior Medical Center, Dedicated Senior Medical Center and JenCare Senior Medical Center. The agreement continues the long-standing relationship that has existed between the two companies for decades and provides stability for Humana's Medicare Advantage members and high-quality care at all three ChenMed brands. The agreement also includes CarePlus Medicare Advantage members in Florida. "ChenMed and our partners at Humana understand seniors, and together we have deep experience delivering on the spectrum of their primary care needs. We look forward to continuing our work with Humana to expand much-needed access to ChenMed's senior-focused concierge care and industry-leading patient outcomes," said Michael Redmond, Chief Financial Officer of ChenMed. "We are excited about this agreement, which guarantees our patients will continue to have access to Humana's leading health plans, along with the personalized, high-touch care we provide."

09:16 EST Avantax appoints Melissa Loner as CCO - Avantax announced the appointment of Melissa Loner, AIF as Vice President and Chief Compliance Officer .Loner joins Avantax from Premier Wealth Management where she was Executive Vice President, Advisor Services.

09:13 EST TELEMEDICUS Inc. trading halted, news pending

09:10 EST Celanese expanding portfolio of sustainable products across Acetyl Chain - Celanese announced the availability of more sustainable versions of multiple Acetyl Chain materials with mass balance bio-content. These offerings will be designated as ECO-B, consistent with the innovative bio-based offerings introduced for Engineered Materials customers in previous years. While many Acetyl Chain solutions already help customers to improve sustainability by reducing waste and materials usage, this expanded product portfolio provides an opportunity to take an additional step with an offering that is chemically identical to the standard products...Celanese will also offer ECO-B versions of other Acetyl Chain intermediate chemicals including acetic acid, vinyl acetate monomer, amines, acetate esters and anhydrides, all designed to help support customers in developing more sustainable product offerings for their downstream markets. Celanese chemicals are essential to the end production of a wide range of products, with applications like pharmaceutical solvents, crop protection, photovoltaics, cleaning products, inks, lubricants, and engineered foams potentially seeing the most immediate benefit from ECO-B options. All Acetyl Chain ECO-B products are now available for commercial orders and delivery time will vary based on product and region-specific details.

09:09 EST CVS Health says Oak Street Health deal has long term growth, earnings power - Expects to maintain "mid-threes" debt/EBITDA ratio over next few years. Expects "modest" share repurchases in 2024/2025.

09:07 EST Digital subsidiary announces Goodcents' plan to maintain certified clean progam - Shield Products, a subsidiary of Digital Ally, announced its customer, Goodcents Deli Fresh Subs' intention to continue its Certified Clean Program within every restaurant in its franchise system. Shield Products is also announcing a strategic alliance with Trust Think Products, as the two companies have a like-minded approach in fighting germs and illnesses through natural product solutions. The Goodcents Certified Clean Program includes the installation of a ThermoVu non-contact temperature check device at the entrance of each location. The device is to be used by all crew members and is also available for guests. "It's great to see partners like Goodcents taking measures to protect and care about their customers and employees," said Brody Green, President of Digital Ally, adding, "The Certified Clean Program is a clear prioritization of the safety of its guests and team members, along with the important display that customers can visit their neighborhood Goodcents with full confidence in the cleanliness of the restaurants.

09:05 EST Nano Dimension announces new patent for cloud manufacturing platform - Nano Dimension announced it has been granted a patent the area of artificial intelligence, AI, and more specifically relating to the neural network that supports its cloud-based manufacturing platform. The granted patent relates to "Cluster-Connected Neural Network." It includes an extensive list of claims involving training and deployment of neural networks. This patent and the technology around it allow DeepCube AI solutions to run more effectively on a distributed network of 3D printers deployed throughout the world. This patent adds to an existing library under DeepCube, which now has 20 granted and 25 filed pending. Nano Dimension as a whole has over 81 granted and 194 filed pending. Yoav Stern, Chairman and Chief Executive Officer of Nano Dimension, shared: "When we acquired DeepCube, it was under the premise that 3D printing, or additive manufacturing, was ripe for disruption with AI. With this in mind, we have and continue to see deep learning-based AI as a key to driving the throughput and yield improvements that will take our advanced manufacturing solutions to the next level. These patents, and the others like them, are clear examples of the hard work that is coming to fruition. It is difficult to imagine these achievements without the Deep Learning dedicated leaders we have in our DeepCube Group. Our customers are noticing the difference that these technologies enable."

09:03 EST Fortinet launches Cybercrime Atlas initiative - Fortinet announced the launch of the Cybercrime Atlas, a joint initiative launched this month in Davos at the organization's Annual Meeting by the World Economic Forum with the support of Banco Santander, Fortinet, Microsoft, and PayPal. The Cybercrime Atlas - currently hosted by the Forum - will aid industry, law enforcement, and government agencies by providing a first-of-its-kind visibility to disrupt cybercriminals across their ecosystem and infrastructure to track and help take down cybercriminals and their infrastructure around the world.

09:03 EST LyondellBasell, KIRKBI invest in APK to develop recycling technology - LyondellBasell and KIRKBI A/S, the family-owned holding and investment company of the LEGO brand, announce they have signed an agreement to make an investment in APK, which specializes in a unique solvent-based recycling technology for low density polyethylene. Under the agreement, LyondellBasell and KIRKBI will become minority shareholders in APK and together with other co-investors will invest approximately 130M Euros in APK. Further Newcyling Plants are planned to be built to increase the production capacity.

08:58 EST Under Armour expects macroeconomic backdrop to remain uneven in 2023 - Says expects year-end inventory growth to be the peak. Says on track to deliver full year financial and operational goals. Sees FY23 adjusted operating income $290M-$310M Sees FY23 tax rate mid single digits. Says expects macroeconomic backdrop to remain uneven in 2023. Comments and guidance taken from Q3 earnings conference call.

08:46 EST Hoth Therapeutics reports results of is AD's therapeutic HT-ALZ - Hoth Therapeutics announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model, supporting the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis. HT-ALZ is a therapeutic in development under the 505 pathway for the treatment of dementia related to Alzheimer's disease, or AD. Hoth reports that the longer treatment before beginning of testing is improving performance of more mice in the water maze and appears to have a positive effect on anxiety-like behavior in the elevated plus maze. The groups of mice treated with the higher doses, 20mg/kg and 40mg/kg of HT-ALZ, appear to have the most benefit, with the 20mg group already showing significant improvement in spatial memory in the water maze. The elevated plus maze test is one of the most widely used tests for measuring anxiety-like behavior. The test is based on the natural aversion of mice for open and elevated areas, as well as on their natural spontaneous exploratory behavior in novel environments.

08:43 EST Mynaric delivers CONDOR Mk2terminals to Telesat Government Solutions - Mynaric (MYNA) announced the delivery of multiple CONDOR Mk2 optical communications terminals to Telesat Government Solutions, a wholly-owned U.S.-based subsidiary of leading satellite operator Telesat (TSAT). Mynaric's first delivery of flight-ready CONDOR optical communications terminals for space applications marks an important milestone towards the product family's space flight heritage. Next, the terminals will be mounted to the Croupier satellites as part of the Defense Advanced Research Projects Agency's Blackjack Track B program and subsequently launched to space to commence the mission's operations.

08:42 EST Kubient builds on propriety KAI platform by announcing KAI 2.0 - Kubient announced the release of KAI 2.0, the latest update to its proprietary ad fraud identification and prevention technology, Kubient Artificial Intelligence. KAI 2.0 comes with improvements for the entire suite of KAI functionalities, including: Expanded real-time AI with 25 algorithms running in under 10 milliseconds and built-in efficiencies to significantly expand the number and complexity of algorithms in the future; Full support for the much larger scale IPv6 protocol; Extensive supply path optimization support with ads.txt and Sellers.JSON/ SupplyChain Object verification; Enhanced support for new CTV and audio formats. "While ChatGPT has shown the public the productive power of what AI can bring, fraudsters are using similar AI tools to continue building their arsenal for fake websites, apps, digital media impressions, etc. This launch ensures that our core AI technology stays many steps ahead of the fraudsters with significant AI firepower to thwart their efforts," said Leon Zemel, Chief Product Officer of Kubient. "At the same time, this release drives significant feature benefits for our publisher and advertiser clients. It's exciting to think about the roadmap ahead as we continue to add

08:40 EST Jaguar Health regains compliance with Nasdaq minimum bid price rule - Jaguar Health announced that on February 7, 2023 the Company received formal notice from The Nasdaq Stock Market that Jaguar has regained compliance with Nasdaq's minimum bid price requirement.

08:40 EST LuxUrban in MLA deals for LA hotel O and 101 Bogart Street in NY, no terms - LuxUrban Hotels announced that it has signed separate, multi-year Master Lease Agreements MLAs to operate two short-term stay hotels: The O Hotel in downtown Los Angeles, CA via a 20-year MLA, inclusive of options; and 101 Bogart Street in Brooklyn, NY via a 10-year MLA. The O Hotel establishes LuxUrban's presence in Los Angeles and 101 Bogart Street increases the Company's property density in New York City. These short-term stay hotels will be marketed to business and vacation travelers via the Company's consumer facing LuxUrbanTM brand. Inclusive of these new properties, LuxUrban has 17 short-term stay hotels under lease in Los Angeles, Miami, New Orleans, New York

08:38 EST Edible Garden closes upsized $10.2M underwritten public offering - Edible Garden announced the closing of its upsized underwritten public offering of 1,619,000 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $6.30 per unit. The warrants in the units are immediately exercisable at a price of $6.30 per share and expire five years from the date of issuance. The shares of common stock and accompanying warrants can only be purchased together in this offering, but were issued separately and were immediately separable upon issuance. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $10.2 million. Edible Garden has also granted the underwriters an option to purchase an additional 242,850 shares of common stock and/or additional warrants to purchase up to 242,850 shares of common stock, to cover over-allotments, of which Maxim Group LLC has exercised its option to purchase additional warrants to purchase 242,850 shares of common stock. Maxim Group LLC acted as lead book-running manager and Joseph Gunnar and Co. acted as joint book-running manager in connection with this offering.

08:37 EST CVS Health says ability to generate cash 'remains strong' - Says "remains confident in adequacy of reserves." Says liquidity/capital position "remain excellent." Expects Signify Health transaction to have "small effect" on FY23 results. Expects lowest contribution to FY earnings in Q1.

08:35 EST Herc Holdings increases quarterly dividend 10% to 63.25c per share - Herc Holdings announced that its board of directors has increased the company's quarterly dividend by 57.5c per share, or 10%, to 63.25 per share. The dividend is payable March 9 to shareholders of record as of February 22.

08:34 EST Verizon named NFL's official private wireless network - Verizon Business announced a five-year partnership deal with the National Football League, NFL, to deliver a Managed Private Wireless Solution across each of the 30 U.S. NFL stadiums. This solution includes full support for coach-to-coach communications on the field and provides the NFL with speed, security and reliability for critical on field coach-to-coach communication. Verizon will showcase this solution in a 30-second commercial spot "Next Season Starts Now," slated to air immediately following the Super Bowl LVII broadcast on Feb. 12. "In an NFL game, every moment matters - seconds matter - as the margin between winning and losing is miniscule. The backbone of world-class play on-the-field is communication," said Sowmyanarayan Sampath, CEO, Verizon Business. "The NFL understands and leans into the power of innovation and technology and this Managed Private Wireless solution deployment is a testament to how the NFL uses the latest technology for the game."

08:33 EST Brookfield Reinsurance to acquire Argo Group in $1.1B transaction

08:32 EST Uber sees West Coast trips approaching pre-Covid levels

08:30 EST Argo Group trading halted, news pending

08:23 EST Sonnet announces pricing of $15M underwritten public offering - Sonnet BioTherapeutics announced the pricing of an underwritten public offering of 13,888,888 shares of common stock or common stock equivalents and investor warrants to purchase up to an aggregate of 27,777,776 shares of common stock. Each share of common stock is being sold together with one investor warrant to purchase two shares of common stock at a combined offering price of $1.08, for total gross proceeds of approximately $15.0 million, before underwriting discounts and commissions and offering expenses payable by Sonnet. The investor warrants have an exercise price of $1.08 per share, are exercisable for a period of five years and contain an alternative cashless exercise provision whereby, subject to certain conditions, a warrant may be exchanged cashlessly for shares of common stock at the rate of half a share of common stock per full share otherwise issuable upon a cash exercise. The offering is expected to close on or about February 10, 2023, subject to the satisfaction or waiver of customary closing conditions. Chardan and EF Hutton, a division of Benchmark Investments, LLC, are acting as joint book-running managers in connection with the offering. Sonnet anticipates using the net proceeds from the offering for research and development, including clinical trials, working capital and general corporate purposes.

08:20 EST Uber looking to deliver GAAP operating profit 'at some point this year'

08:18 EST Medigus: Elbit Systems, ScoutCam complete development stage in RTVM program - Medigus announced that ScoutCam and Elbit Systems completed a major development stage in the use of ScoutCam's real time video monitoring system. During the development stage, the RTVM system used on Elbit Systems' UAS platform acted as a replacement of manual pre and post flight visualization inspections of the aerial platform and provided clear visibility of areas that had previously been inaccessible to maintenance and operations teams. In addition, ScoutCam's RTVM provided visibility even when the operating ambience was not suitable for continuous real-time monitoring.

08:16 EST Uber sees ordering, rides frequency continuing to rise

08:14 EST Fortress Biotech prices $13.9M registered direct offering - Fortress Biotech announced that it has entered into definitive agreements for the issuance and sale of 16.6 million shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share is $0.835. Certain directors and officers of the Company participated in the offering and purchased an aggregate amount of approximately $3.3 million of Fortress common stock at the same purchase price of $0.835 per share, which is at a premium to the consolidated closing bid price under Nasdaq rules. In a concurrent private placement, investors in the registered direct offering will also receive a pro rata right to acquire, in the aggregate, securities exercisable into approximately 3.5% of the outstanding shares of common stock in each of the Company's next 20 new operating subsidiaries. The Contingent Subsidiary Securities will only be issued to the extent such a new operating subsidiary first consummates a specified corporate development transaction within the next five years, and will be exercisable immediately upon issuance, with an exercise period of 10 years, at an exercise price equal to the fair market value of one share of common stock of the subsidiary on the date of the corporate development transaction. The issuance of the rights and Contingent Subsidiary Securities are conditioned on the approval of the Company's stockholders to the extent required by Nasdaq Listing Rule 5635. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The offering is expected to close on or about February 10, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $13.9 million. Fortress expects to use the net proceeds from the offering for general corporate purposes and working capital.

08:13 EST Verses Technologies enters service agreement with ShareIntel - VERSES Technologies negotiated and executed a service agreement with ShareIntel Shareholder Services, as part of its continued commitment to protecting investors and maximizing shareholder value. Through ShareIntel's patented, proprietary service offerings, VERSES is able to obtain trading analytic metrics that are designed to help coordinate, monitor and enhance corporate governance, shareholder communication, regulatory compliance, and surveillance of trading in the Company's shares, allowing the Company to better monitor trading activity, including potential violations of SEC Regulation SHO, which governs stock and option share locate, close out, and fail to deliver requirements. VERSES is committed to taking all necessary actions to protect the interests of its shareholders and will continue to work with ShareIntel and other partners to combat illegal short selling and ensure fair market conditions.

08:10 EST First Merchants appoints Chiang to board of directors - First Merchants Corporation has appointed Dr. Mung Chiang to the Board of Directors of First Merchants Corporation and First Merchants Bank. Dr. Chiang, President of Purdue University, is a strong advocate of partnerships that effectively drive strong and sustained economic growth and vitality in Indiana and across the Midwest. With the addition of Dr. Chiang, First Merchants will have a 15-member board, including 13 independent outside directors. Dr. Chiang will be on the ballot for continuing terms at the Corporation's Annual Shareholder Meeting in May 2023.

08:10 EST Lexagene Holdings provides update on work with biopharma customers - LexaGene Holdings provides the following update on the Company's efforts to have the MiQLab System adopted for routine testing during the manufacturing of biologics. Jack Regan, CEO and Founder of LexaGene commented, "We continue to work with both of our biopharma customers - a more traditional biopharma company with a market cap that is greater than$100B and a leading Contract Drug Manufacturing Organization with a market cap that is greater than$40B. Individuals in both organizations have indicated that our technology has the potential to benefit their respective companies and that our technology can be of great value to the entire industry. We have sold our technology into the R&D groups of both companies. Although this is a critical first step, our goal is to get into manufacturing where regular testing at an average-sized plant could generate ~ $5M in revenue per year, and the entire annual testing market opportunity is estimated to be $10B in size. For our traditional biopharma customer, the execution of the feasibility studies was a great start and they have set aside time in April to start to a formal campaign within their facility that will focus on using the MiQLab System in the optimization of different manufacturing unit operations. These studies will include testing for Mycoplasma. Per request from this customer, we have designed highly sensitive, RNA-based assays for bacteria and Minute Virus of Mice and we are about to start designing an assay for Vesivirus 2117, as these contaminants are of highest interest for them. During our conversations with our traditional biopharma customer, they suggested presenting at the 2023 National Institute for Innovation in Manufacturing Biopharmaceuticals National Meeting being held in June in Washington, DC. NIIMBL is a public-private partnership whose mission is to accelerate biopharmaceutical innovation and advance other industry objectives. Our CDMO customer is in the process of submitting the data they've generated using a MiQLab System for a presentation at the 15th Annual Bioprocessing Summit, which is to be held in August in Boston, MA. The title of their talk is "Risk Reduction by Rapid Automated Detection of Common Biomanufacturing Contaminants." Having our biopharma customers request to present the data they generated using our technology at a conference is a fantastic endorsement and there is no better advertising. This exposure will help LexaGene achieve better brand awareness and wider adoption in the industry."

08:09 EST Bio-Rad and Element Biosciences announce partnership - Element Biosciences, the developer of an innovative DNA sequencing platform disrupting genomics, and Bio-Rad Laboratories announced a partnership to demonstrate the capabilities of the Bio-Rad SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI Benchtop Sequencer. The Element AVITI Sequencing Platform's novel Avidity Sequencing chemistry can be easily adapted for use with the Bio-Rad SEQuoia Complete Stranded RNA Library Prep Kit and the SEQuoia Express Stranded RNA Library Prep Kit to obtain RNA sequencing accuracy and repeatability among samples and different RNA inputs. Recent collaborative studies show high compatibility and performance for RNA sequencing using SEQuoia library preparation chemistries on the Element AVITI System. Bio-Rad will present the results of this collaboration at the Advances in Genome Biology and Technology General Meeting in Hollywood, Florida, on Thursday, February 9 in Presidential Suite 3131 of the Diplomat Resort Hotel.

08:08 EST Uber 'really focused' on efficiency

08:07 EST Sysco partners with two universities to accelerate climate change innovation - Sysco Corporation has launched its new 'Recipe for Sustainability' program. Through this program, Sysco will collaborate with top universities to explore innovations that will accelerate climate action and lead the industry towards a more sustainable future. "Sysco is proud to partner with leading universities to help develop the next generation of sustainability leaders," says Neil Russell, Sysco's SVP Corporate Affairs and Interim Chief Financial Officer. "We're eager to see the bright ideas generated through these partnerships that will help address sustainability challenges faced by our industry, and ultimately reduce our impact on the planet." In 2021, Sysco set an industry-leading science-based climate goal to reduce its direct emissions by 27.5% by 2030. Sysco also committed to engaging supplier partners representing 67% of Scope 3 emissions to set their own science-based targets by 2026.

08:06 EST Gannett sees strategic partnership with Gambling.com as immediately accretive - Gannett (GCI) announced a multi-year strategic partnership with Gambling.com Group Limited (GAMB), a provider of player acquisition services for the regulated global online gambling industry. Under the agreement, Gambling.com Group will provide relevant content for sports enthusiasts while leveraging Gannett's reach across the U.S. media landscape through the USA TODAY Network across the country. "Partnering with Gambling.com Group enables Gannett to have a market-leading, sports-betting authority deliver in-depth reviews, breaking news, and expert insights. Our highly engaged audience of more than 47M sports fans crave analysis and betting insights to make smart decisions and find the best sportsbooks and online casino sites," said Michael Reed, Gannett Chairman and Chief Executive Officer. "We expect this partnership to be immediately accretive to our EBITDA and Free Cash Flow by monetizing our sports traffic. The deal is progressively more valuable as regulated online gambling is launched in more states."

08:06 EST Global Crossing Airlines to operate over 100 cargo flights per year to Cuba - Global Crossing Airlines Group announced it will operate all cargo flights with its A321 Freighter to Havana, Cuba on behalf of OFAC approved operator CubaMax.

08:06 EST DarioHealth announces agreement with DexCom - DarioHealth (DRIO) announced an agreement with Dexcom (DXCM) to integrate its market-leading CGMs, into Dario's multi-chronic condition platform. Dexcom CGM uses a small, wearable sensor to continuously measure and send glucose levels to a receiver or smart device, enabling people with diabetes to make real-time decisions about their health. This agreement enables the integration of data from Dexcom CGMs directly into Dario's metabolic solution, making it easy for people using the wearable device to benefit from Dario's highly personalized support. The integration with Dexcom builds on the collaboration between Dario and Sanofi US which aims to establish an ecosystem of dedicated technology partners and industry-leading digital therapeutics solutions.

08:05 EST Absci announces expansion of Scientific Advisory Board - Absci Corporation announced the expansion of its Scientific Advisory Board with three world-class scientific leaders: Victor Greiff, Ph.D., Timothy Lu, MD, Ph.D., and Hubert Truebel, MD, Ph.D., MBA. These leaders in AI drug design, synthetic biology, and translational medicine, respectively, will play a pivotal role in helping Absci continue to pioneer AI drug creation in its mission to create better biologics for patients, faster. Dr. Victor Greiff is an Associate Professor of Systems Immunology at the University of Oslo. Dr. Greiff's group develops machine learning and experimental tools for analyzing antibody and T-cell repertoires to facilitate the in silico design of immune receptor-based immunodiagnostics and immunotherapeutics. Dr. Timothy Lu is a biotech entrepreneur and Associate Professor of Biological Engineering and Electrical Engineering and Computer Science at the Massachusetts Institute of Technology. Dr. Hubert Truebel is the Chief Medical Officer & Head of Clinical Development at AiCuris. With his 20+ years of academic and industry experience, Dr. Truebel brings an extensive track record of progressing a wide variety of innovative therapeutics through clinical development, agency approval, and ultimately to patients.

08:04 EST H2O Innovation awarded O&M contract, renews existing contract - H2O Innovation announced that it has recently been awarded a new operation and maintenance service contract and has extended three existing contracts. These projects have a total value of $7.1 M, bringing the Corporation's O&M backlog to $149.6 M. The Corporation was awarded a new O&M contract with a commercial customer, which is located in the State of Georgia and for which H2O Innovation had already provided a decentralized wastewater reuse system that transforms wastewater generated on site into clean water for cooling tower and boiler use. This two-year contract started in January 2023. H2O Innovation has also renewed, for a five-year period, the O&M contract for the Kananaskis Region of Alberta. The contract consists of the operation and maintenance of 11 potable water treatment systems and two wastewater treatment systems, including 28 sewage lift stations. Finally, the Corporation has extended a contract for a municipality in the State of New Hampshire for an additional period of two years, as well as a contract in the State of New York for a three-year period.

08:02 EST Creative Medical Technology receives IRB approval for clinical trial of CELZ-201 - Creative Medical Technology Holdings announced that it has received Institutional Review Board, or IRB, approval to proceed with its Clinical Trial for the treatment of Type 1 Diabetes with its CELZ-201 cell therapy. The FDA had previously cleared the Company's Investigational New Drug, or IND, application within 30 days from submission. The Company believes that CELZ-201 leverages a unique approach to harnessing the power of Perinatal Tissue Derived Cells, or PRDC, to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, and large-scale clinical expansion. The primary objective of the study is to evaluate CELZ-201 as a treatment for patients with newly diagnosed Type 1 Diabetes. The company sponsored trial will be conducted at the University of Miami Health System in conjunction with the Diabetes Research Institute.

07:56 EST Johnson Controls and Willow announce global collaboration - Johnson Controls and Willow, a leading provider of digital twin solutions for critical infrastructure and real estate announced a global collaboration to digitally transform buildings and facilities into healthier, safer and more sustainable environments for their customers and occupants. Johnson Controls and Willow have committed to jointly bring next-generation solutions to their customers. Digital twins are playing an increasingly important role in the design, construction, and ongoing operation of healthy buildings and facilities and can be particularly valuable when analyzing large datasets and predicting patterns and trends. In connection with this collaboration, Johnson Controls and Willow have entered into a go-to-market agreement and license agreement for the use of digital twin technology patents held by Johnson Controls. The companies also agreed to strengthen their technology and business collaboration in marketing, implementation and interoperability.

07:43 EST Rekor Systems selected for federal agency deployment - Rekor Systems announced that the Company's AI-driven roadway intelligence software has been selected for a national security related application for a federal agency. The Company received a purchase order extension of more than $900,000 for one-year software subscription for the Company's AI roadway intelligence software.

07:42 EST Society Pass subsidiary signs MoU with PT. Kereta Cepat Indonesia-China - NusaTrip, Indonesia's first IATA-certified online travel agency and the travel vertical of Society Pass, formally announces the signing of a Memorandum of Understanding, MoU, with PT. Kereta Cepat Indonesia-China, KCIC, as a preferred online ticket sales partner for Kereta Cepat Jakarta-Bandung, KCJB, the first fast train service between Jakarta and Bandung in Indonesia. Established to develop mass transportation infrastructure for Indonesia's railroad system, PT KCIC is currently the owner of the Jakarta-Bandung Fast Train project. NusaTrip is one of the 20 selected partners by KCIC, from private to state-owned companies and its affiliates. The MoU formalizes partnerships covering various aspects of KCJB services starting from ticket sales, to payment systems, to area development and accessibility, to integration of transportation modes, and to application of renewable energy. The President Director of KCIC, Dwiyana Slamet Riyadi, stated that this collaboration was part of KCJB's primary operational preparation in order to provide the best quality service and positive impacts for the community.

07:42 EST CVS Health sees FY23 CapEx $2.8B-$3B - Sees FY23 adjusted effective tax rate ~25.5%.

07:41 EST Uber entering the year with 'great momentum,' says CEO - In prepared remarks released in conjunction with its Q4 results, Uber CEO Dara Khosrowshahi said the company reached a new milestone in the quarter, crossing 2B trips in a single quarter for the first time, an average of nearly 1M trips per hour. The executive says Uber is entering the year with "great momentum," with Mobility demand accelerating and Delivery remaining resilient. He added that the pandemic's impact on the Mobility business "is now well and truly behind us." The quarter was "challenging" for Uber Freight, the company noted, adding that it continues to expect relatively muted trends in the near-term. Uber Freight reduced headcount by roughly 150 employees in January.

07:40 EST CVS Health sees FY23 Health Care Benefits revenue $101.4B-$102.9B - Sees FY23 total Medical Membership 24.9M-25.3M. Sees FY23 Pharmacy Services revenue $170.2B-$172.7B. Sees total pharmacy claims processed flat to up 1%. Sees FY23 Retail/LTC revenue $108B-$109.7B; prescriptions filled down 4%.

07:39 EST SHF Holdings appoints Racine to board of directors - SHF Holdings announced that Karl Racine has commenced active participation on the Company's Board of Directors following his January 2023 departure from office. Racine previously served as the president of the bipartisan National Association of Attorneys General, which in 2022 awarded him and his team a sitting Attorney General's highest honor: the Kelley-Wyman Award.

07:38 EST Duck Creek Technologies announces expiration of 'go-shop' period - Duck Creek Technologies announced the expiration of the 30-day "go-shop" period under the terms of the previously announced definitive merger agreement, pursuant to which Vista Equity Partners will acquire Duck Creek for $19.00 per share, in an all-cash transaction valued at approximately $2.6 billion. The transaction is expected to close in the first half of 2023, subject to the satisfaction of customary closing conditions, including approval by Duck Creek's stockholders and U.S. antitrust clearance. Upon completion of the transaction, Duck Creek's common stock will no longer be publicly listed, and Duck Creek will become a privately held company.

07:36 EST Syneos Health partners with Equicare, to accelerate clinical trial research - Syneos Health announced a strategic partnership with Equicare to use proXimity, an innovative cloud-based software platform that accelerates the transfer of clinical trial subject data from multiple electronic health records, EHR, to the sponsor's electronic data capture systems, EDC. Through the partnership, Syneos Health will use the proXimity platform to automate sponsor data transfers from EHRs to EDCs for clinical trials, helping to accelerate the performance of new therapies for patients. "At Syneos Health, we are committed to our customers, always. By partnering with Equicare to use proXimity, we are further addressing challenges sites and sponsors face regarding data capture, timelines and quality control," said Michael Henning, President, Clinical Delivery, Syneos Health. "We're confident this collaboration will help enhance the clinical trial experience for sites and sponsors by accelerating data entry and management to improve its accuracy and to help speed new therapies to patients."

07:34 EST Annovis to add European clinical trial sites for Phase 3 study of buntanetap - Annovis Bio announced approval for additional European clinical trial sites for the ongoing Phase 3 study of buntanetap for the treatment of Parkinson's disease, or PD. Annovis is actively recruiting for the ongoing Phase 3 study with 50 clinical trial sites open and currently enrolling in the US. The approval adds an additional 48 sites in five European Union, or EU, countries, including Italy, Spain, Hungary, Poland and Germany, for the Company's Phase 3 study of buntanetap for the treatment of Early PD. The locations will enroll the initial cohort of early PD patients. Based on the current enrollment, the Company anticipates having a sufficient number of patients who have received two months of therapy to conduct an interim analysis in the Q2. The interim analysis will be used to determine if the Company's original estimates for patient enrollment in the Phase 3 trial will be sufficient to observe a statistically significant treatment effect in both scales between the active arms and the control arm of the study after six months of treatment. The ongoing Phase 3 trial is a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap in patients with early-stage Parkinson's disease. Patients are being treated with 10mg buntanetap, 20mg buntanetap or placebo, on top of their standard of care, for six months.

07:32 EST Meihua to explore application of ChatGPT technologies - Meihua announced the company will seek to explore the application of ChatGPT technologies to develop online health consultation services and is now actively laying out the research and development of related facilities application and technology platforms. In recent years the company has been continuously exploring the application of intelligent content and data generation technologies to help accelerate the development of online AI health consultation services that often involves collection and analysis of unstructured texts. MHUA will seek to cooperate with research centers in the field and conduct in-depth analysis on the possible application and expansion of ChatGPT related technologies in the Company's endeavors to develop its online AI health consultation services.

07:32 EST CMA says Microsoft-Activision deal 'could harm UK gamers' - A CMA investigation has "provisionally concluded that Microsoft's proposed acquisition of Activision could result in higher prices, fewer choices, or less innovation for UK gamers," the United Kingdom's Competition and Markets Authority announced. "The provisional findings from the Competition and Markets Authority (CMA) follow a wide-ranging investigation conducted over the last five months to understand the market and potential impact of the deal. This has included holding site visits and hearings to hear directly from business leaders at Microsoft and Activision, analysing over 3 million internal documents from the two businesses to understand their views on the market, commissioning an independent survey of UK gamers, and gathering evidence from a range of other gaming console providers, game publishers, and cloud gaming service providers," the regulator stated. "The CMA welcomes responses from interested parties to its provisional findings by 1 March 2023 and its notice of possible remedies, which sets out potential options for addressing its provisional concerns, by 22 February 2023. These will be considered ahead of the CMA issuing its final report, which is due by 26 April 2023," the regulator added. Reference Link

07:28 EST Indaba issues letter to ON24's board on capital returns, governance - Indaba Capital Management , which is the second largest shareholder of ON24, Inc. ON24" with an ownership interest of nearly 9% of the Company's outstanding shares, today issued an open letter to the Company's Board of Directors . "As you know, Indaba is ON24's second largest shareholder. We are strong proponents of ON24 enacting a meaningful capital return program, a plan to achieve profitability and corporate governance enhancements. We believe these actions are necessary in light of the Company's approximately 80% share price decline over the past two years. Unfortunately, the need for change at ON24 is evidenced by much more than just objectively terrible shareholder returns. ON24 has a classified Board, long serving directors, no shareholder representative in the boardroom and a history of excessive spending and questionable capital allocation under Co-Founder and Chief Executive Officer Sharat Sharan. These apparent issues are all the more concerning when taking into account that ON24 had a hoard of cash, cash equivalents and marketable securities on its balance sheet as of the end of its last reporting period."

07:25 EST CMS grants Spectrum permanent J-Code for Rolvedon injection - Spectrum Pharmaceuticals announced that a permanent J-code, J1449, has been issued for ROLVEDON or eflapegrastim-xnst Injection by the U.S. Centers for Medicare & Medicaid Services CMS effective as of April 1 . "This is an important milestone in the ROLVEDON launch. A permanent J-code will enable a more efficient and predictable reimbursement in the outpatient setting. The combination of a permanent J-code on April 1, 2023 and ROLVEDON'S inclusion in the National Comprehensive Cancer Network Supportive Care Guidelines (NCCN Guidelines announced on December 6 are key elements in establishing brand awareness and building customer confidence in our novel product," said Tom Riga, President and Chief Executive Officer of Spectrum Pharmaceuticals. J-codes are permanent reimbursement codes used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for Medicare Part B drugs like ROLVEDON that are administered by a physician. Claims submission and documentation are simplified with a permanent J-code, facilitating and streamlining the billing and reimbursement process.

07:20 EST Wolverine sells Keds brand to Designer Brands, no terms given - Wolverine World Wide (WWW) that it has sold the Keds brand to Designer Brands (DBI), the parent company of footwear retailer DSW. In addition, the Company announced that it intends to grant an exclusive license to DBI for Hush Puppies footwear in the United States and Canada, where DSW has been the exclusive retail partner for Hush Puppies since last year. Selling Keds and licensing the Hush Puppies brand for the United States and Canada is an important step as we continue to advance our strategy to simplify the portfolio and direct resources to our growth brands. We are confident this will place Wolverine on an accelerated path to improved profitability and long-term shareholder value creation," said Brendan Hoffman, Wolverine Worldwide's President and Chief ...The proceeds will be used to pay down debt and strengthen our capital structure," added Hoffman. The Keds brand sale closed effective February 4,, and the Hush Puppies license is anticipated to be effective as of July 1. The Company will provide more information on the impact of these transactions in its upcoming earnings call scheduled for February 22. The Company also noted that its evaluation of strategic alternatives for the Wolverine Leathers business is ongoing.

07:16 EST Reynolds Consumer Products reports Q4 EPS 53c, consensus 57c - Reports Q4 revenue $ $1.09B , consensus $ $1.11B .

07:14 EST Orchard Therapeutics announces comprehensive presence at WORLDSymposium - Orchard Therapeutics announced a series of presentations from across its neurometabolic portfolio will be featured at the 19th Annual WORLDSymposium taking place February 22-26, 2023, in Orlando, Florida. Featured presentations include results from an updated integrated analysis of 39 patients with metachromatic leukodystrophy treated in clinical trials or under expanded access frameworks in Europe with OTL-200, currently marketed as Libmeldy in the European Union, UK, Iceland, Liechtenstein and Norway, several accepted abstracts highlighting newborn screening efforts to support the timely and accurate diagnosis of MLD, as well as an encore clinical data presentation from the company's investigational hematopoietic stem cell gene therapy OTL-201 for MPS-IIIA. Other data highlights include several investigator-initiated presentations detailing results of patients treated with OTL-200 in Europe, the U.S. and South America on compassionate use basis with drug product supplied from a European commercial manufacturer, demonstrating the potential for global supply from a centralized cGMP manufacturing site.The company will also host a sponsored symposium on Wednesday, February 22, 2023, from 11:45 a.m. to 12:45 p.m., titled "From Assay to Application: Writing the roadmap for metachromatic leukodystrophy newborn screening," featuring expert speakers with deep experience across the diagnostic journey and continuum of care for children with inborn errors of metabolism who will discuss the evidence to support widespread newborn screening for MLD.

07:10 EST Dorman Products launches 400 new repair solutions - Dorman Products announced the release of 400 new motor vehicle parts, including 130 aftermarket exclusives. The new products advance Dorman's mission of providing repair professionals and owners greater freedom to fix passenger, commercial, and recreational vehicles with internal combustion, hybrid, and electric powertrains. Among the new releases are a dozen innovative Dorman OE FIX repair solutions. This month's new releases include two more additions to Dorman's comprehensive array of components and accessories for turbochargers. A new turbo air intercoolerand boost pressure relief valve, engineered to fit a total of roughly 3.5 million popular Ford and Lincoln vehicles, are being introduced in February. "The new intercooler and pressure relief valve are just the latest additions that reinforce our position as a leader in the aftermarket for turbocharger system components and accessories," said Chris Gillespie, Category Director for Dorman's turbocharger line. Dorman is also reinforcing its position as a premier manufacturer of upgraded engine heater hoses designed to eliminate the most common failure point of that part category: the original equipment's plastic connectors, which tend to crack and leak.

07:09 EST Green Thumb Industries publishes inaugural Social Impact Report - Green Thumb Industries announced the release of its inaugural Social Impact Report, which provides an overview of the Company's most recent initiatives across its four "Growing for Good" pillars: Community Engagement; Diversity, Equity & Inclusion; Restorative Justice; and Environmental Stewardship. "Creating a positive impact in communities has been a core part of Green Thumb's mission since our founding. Cannabis has the power to spread positivity in endless ways, and our goal is to amplify that impact through our Growing for Good program," said Green Thumb Founder, Chairman and Chief Executive Officer Ben Kovler. "While I am incredibly proud of our progress, there is still a lot to be done. We are committed to building on our efforts and look forward to sharing our continued progress."

07:08 EST BioXcel Therapeutics to host BXCL701 KOL Day - BioXcel Therapeutics will host a Key Opinion Leader Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET. Vimal Mehta, Ph.D., CEO, and Vincent O'Neill, M.D., Chief R&D Officer, OnkosXcel Therapeutics, a wholly owned subsidiary of BioXcel Therapeutics, Inc., will be joined by a panel of leading oncology experts to review top-line Phase 2 data results being presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, and the development path and future opportunities for BXCL701, which is currently being developed for the potential treatment of small cell neuroendocrine prostate cancer, an aggressive variant of prostate cancer.

07:06 EST GXO Logistics expands partnership with Robotic Assistance Devices - GXO Logistic announced it is expanding its technology partnership with Robotic Assistance Devices, RAD, a subsidiary of Artificial Intelligence Technology Solutions. GXO is developing advanced security solutions with RAD to improve the safety and efficiency of its customers' logistics operations. "GXO's customers depend on our technological expertise and operational excellence and having a robust security program is a key part of the solution suite we offer," said Thomas Nelson, Senior Director of Security at GXO. "By combining our logistics expertise with RAD's innovative robotics, we've deployed even more cost-effective solutions that didn't exist just a few years ago. We look forward to continuing our partnership with RAD as we increase safety and drive efficiencies for our customers."

07:03 EST Ideanomics, MAHLE form strategic partnership - Ideanomics announced that it has formed a strategic partnership with the German company MAHLE, and will become the development partner and exclusive North American distributor for the chargeBIG 18-36 AC fleet charging solution. Customers can order the unit from Ideanomics beginning in Q2 2023, with first orders expected to be fulfilled in early 2024.

07:02 EST Uber up 7% in pre-market trading after Q4 report - Uber shares are up $2.48, or 7%, to $37.38 in pre-market trading.

06:57 EST Invesco CEO Marty Flanagan to retire, Andrew Schlossberg to succeed - Invesco announced that Marty Flanagan has decided to retire as president and CEO on June 30. Flanagan will also step down from the Invesco board on June 30. He will continue as chairman emeritus through December 31, 2024, providing advice and guidance to the company. The Invesco board of directors announced the appointment of Andrew Schlossberg, senior managing director and head of the Americas, to succeed Flanagan as president and CEO of Invesco. Schlossberg will become president and CEO of Invesco and a member of the Invesco board of directors on June 30.

06:35 EST Coty raises FY23 adjusted EPS 35c-36c view from 32c-33c - Consensus is for FY23 EPS 32c. Reaffirms FY23 adjusted EBITDA view $955-965M. Coty continues to see strong demand growth across nearly all markets, particularly in Prestige fragrances, with Coty maintaining strong launch activity in both Prestige and Consumer Beauty. At the same time, the component shortages which limited Coty's Prestige fragrance growth in Q2 have begun to ease, including a sequential improvement in January service levels. The combination of improved service levels and ongoing strength in beauty consumption is driving a sequential acceleration in Coty's January sales growth. These trends underpin the Company's confidence in its FY23 outlook, which is inline with its medium term growth algorithm. The Company continues to anticipate adjusted EPS growth of approximately 20% in FY24 and beyond fueled by lower interest expenses as part of its deleveraging efforts, consistent with its medium-term targets. Coty continues to expect FY23 revenues for the core business, adjusting for the impact of the Russia exit, to grow 6-8% LFL, with revenue growth trends in 2H23 consistent with this range. The exit from Russia is estimated to negatively impact FY23 sales by approximately 2%, including an approximate 2% impact in Q3 and none in Q4. Based on current exchange rates, the Company now anticipates FX headwinds towards the better end of its prior outlook of -6-8%. This FX outlook includes a mid-single-digit negative impact on sales in Q3 and a low-single-digit negative impact in Q4. Coty continues to expect modest gross margin expansion in FY23, despite the elevated inflationary environment, aided by savings as well as solid pricing execution, including mid-single-digit pricing increases exiting Q1 and another round of mid-single-digit pricing going into effect exiting Q3. In addition, the Company continues to target leverage towards 3x exiting CY23 and approximately 2x exiting CY25.

06:33 EST Evaxion Biotech, Pantherna announce promising preclinical mRNA vaccine data - Evaxion Biotech and Pantherna Therapeutics announced preclinical proof of concept for the combination of the two companies' key technologies. The preclinical data demonstrate that tumor neoantigens identified by Evaxion's AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model when delivered using Pantherna's proprietary lipid nanoparticle mRNA platform. "We are extremely pleased with the preclinical data that clearly demonstrate the potential for our combined technologies. The data provide further evidence that immunogenic sequences identified by Evaxion's AI platforms are able to drive a relevant immune response on multiple vaccine platforms, including mRNA. This opens up many opportunities in our current and future immuno-oncology and infectious disease programs," says Birgitte Rono, CSO at Evaxion. In continuation of these positive findings, Evaxion and Pantherna will further explore optimal LNP formulations to effectively deliver mRNA and DNA-encoded antigens identified by Evaxion's AI platforms.

06:09 EST Coherent transfer listing to NYSE from Nasdaq - Coherent announced that it is transferring the listing of its common stock and its 6.00% Series A Mandatory Convertible Preferred Stock to the New York Stock Exchange from The Nasdaq Stock Market. The company expects that its common stock and 6.00% Series A Mandatory Convertible Preferred Stock will cease trading on Nasdaq at the close of trading on Wednesday, February 22. The Company expects that its common stock and 6.00% Series A Mandatory Convertible Preferred Stock will begin trading on the NYSE on Thursday, February 23, under the ticker symbols of "COHR" and "IIVI", respectively.

06:06 EST Maxar Technologies awarded $192M contract by the NGA - Maxar Technologies announced that it was awarded an indefinite delivery, indefinite quantity, or IDIQ, contract by the National Geospatial-Intelligence Agency, or NGA, worth up to $192M over five years. Under the Foreign Commercial Imagery Program contract, Maxar will provide multiple U.S. allies and partners with commercial imagery services consisting of high-resolution electro-optical, synthetic aperture radar, or SAR, and 3D data products. To support these contract requirements, Maxar will leverage the following products: SecureWatch, Rapid Access Program, Precision3D, and Commercial SAR.

06:02 EST UniFirst to acquire Clean Uniform for $300M - UniFirst announced that it has signed an agreement to purchase Clean Uniform for $300M, or a net purchase price of approximately $260M after adjusting for the estimated value of anticipated incremental tax benefits that it expects to realize over time. Founded in 1938 and headquartered in St. Louis, MO, Clean Uniform is one of the largest independent uniform, workwear and facility service program providers in the United States with 11 locations covering Missouri, Illinois, Arkansas, Kansas and Oklahoma and annual revenue of approximately $90M. The acquisition is structured primarily as a stock purchase but from a tax perspective will be treated as an asset purchase, which will allow for a step-up in the tax basis of the assets and provide incremental tax benefits valued at approximately $40M. UniFirst Management will provide additional details on the estimated impact of the acquisition on its fiscal 2023 financial results during its quarterly earnings call scheduled at the end of March 2023. The Board of Directors of UniFirst unanimously approved the transaction. The acquisition is expected to close in the Company's third fiscal quarter ended May 27, subject to customary closing conditions and regulatory approvals. UniFirst will finance the transaction through the use of its cash reserves and availability under its existing line of credit.

05:11 EST Fanhua to acquire 51% of equity interests in Wuhan Taiping Online - Fanhua announced that it has signed a definitive agreement with the existing shareholders of Wuhan Taiping Online to acquire 51% of the equity interests of Taiping. The transaction is expected to be completed in the first quarter, subject to certain customary conditions. Pursuant to the agreement, the company will acquire 51% of the equity interests of Taiping with stock considerations of up to 455,357 American Depositary Shares. Taiping is estimated to generate gross written premiums of no less than RMB 160 and net income of RMB 10M in 2025, representing compound annual growth rates of 40% and 26% from 2023 to 2025, respectively. The stock consideration, adjustable based on the achievement of certain performance targets in the next three years by Taiping, is subject to a lock-up period of three years and will be released from lock-up in two batches after 2025. Taiping has run a successful business through the implementation of the 'Triple-R' marketing model. It boasts a highly productive sales force with per capita productivity of over RMB 600,000, far above the industry average.